Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Phthalide compound medication and medication compounds thereof

A technology for pharmaceutical compositions and compounds, which can be used in drug combinations, pharmaceutical formulations, anti-tumor drugs, etc., can solve problems such as cancer cell growth, abnormal metabolism and abnormality of surrounding tissues, and achieve the effects of preventing abnormal metabolism and inhibiting growth.

Inactive Publication Date: 2016-03-09
SUN YAT SEN UNIV
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, insufficient oxygen intake may lead to metabolic abnormalities or functional abnormalities of the organs and surrounding tissues, which may lead to various diseases such as hypertension, cardiovascular disease, and neurodegenerative disease , may also cause the growth of cancer cells
A prior art method widely used in the treatment of anemia involves blood transfusion, however, this prior art method is only a passive therapy and other treatments must be administered at the same time to avoid the side effects caused by blood transfusion; for example, it is necessary to administer Give iron-chelating agent (iron-chelating agent) to reduce the iron content in the blood and prevent the patient from developing iron poisoning (iron-poisoning)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Phthalide compound medication and medication compounds thereof
  • Application of Phthalide compound medication and medication compounds thereof
  • Application of Phthalide compound medication and medication compounds thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0050] In order to make the above-mentioned and other objects, features and advantages of the present invention more comprehensible, the preferred embodiments of the present invention are specifically cited below, together with the accompanying drawings, and are described in detail as follows:

[0051] The phthalide compound of the present invention can form at least one hydrogen bond with the Arg141 residue of the alpha subunit of a hemoglobin, a hemoglobin variant, a recombinant hemoglobin or a hemoglobin-based blood substitute to stabilize the hemoglobin, the Alpha of the hemoglobin variant, the recombinant hemoglobin or the hemoglobin-based blood substitute 1 、α 2The interface between the subunits (α1 / α2 interface) promotes the hemoglobin, the hemoglobin variant, the recombinant hemoglobin or the hemoglobin-based blood substitute to stabilize in the T state of low oxygen affinity to help the hemoglobin, The hemoglobin variant, the recombinant hemoglobin or the hemoglobin-...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A method for improving the oxygen-releasing ability of hemoglobin, hemoglobin variants, recombinant hemoglobin and hemoglobin-based blood substitutes to organs and peripheral tissues in human bodies is disclosed by administering a compound of phthalides to a subject in need thereof to improve the oxygen-releasing ability of hemoglobin, hemoglobin variants, recombinant hemoglobin and hemoglobin-based blood substitutes to the organs and the peripheral tissues in human bodies. The compound of phthalides is characterized by a phthalide functional group, and forms at least one hydrogen bond with [alpha]Arg141 of hemoglobin, hemoglobin variants, recombinant hemoglobin and hemoglobin-based blood substitutes, stabilizing the [alpha]1 / [alpha]2 interface of hemoglobin, further stabilizing the oxygenated hemoglobin, hemoglobin variants, recombinant hemoglobin and hemoglobin-based blood substitutes in the low oxygen affinity 'T' state and facilitating the oxygen release to the organs and the peripheral tissues. A medication for improving the oxygen-releasing ability of hemoglobin, hemoglobin variants, recombinant hemoglobin, and hemoglobin-based blood substitutes to organs and peripheral tissues in human bodies is also disclosed.

Description

technical field [0001] The present invention relates to the use of a phthalide compound, in particular to a phthalide compound used to prepare hemoglobin (hemoglobin, Hb for short), hemoglobin variant (hemoglobinvariant), recombinant hemoglobin (recombinanthemoglobin) or hemoglobin-based The use of drugs that release oxygen to various organs and surrounding tissues in the human body. The present invention also relates to a pharmaceutical composition for enhancing the ability of hemoglobin, the hemoglobin variant, the recombinant hemoglobin or the hemoglobin-based blood substitute to release oxygen to various organs and surrounding tissues in the human body. Background technique [0002] Hemoglobin (hemoglobin, Hb for short) is the protein used to carry and transport oxygen in red blood cells. Hemoglobin in the blood can transport oxygen from respiratory organs such as the respiratory tract and lungs to various organs and surrounding tissues in the human body, and release oxy...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/365A61K31/6615A61P7/00A61P7/06A61P9/12A61P25/06A61P35/00A61P25/28A61K31/192
CPCA61K31/365A61K31/6615A61P7/00A61P7/06A61P9/12A61P25/06A61P25/28A61P35/00A61K31/192
Inventor 王家蓁马汉德余友清
Owner SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products